Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | Q0245 |
Short Description | Bamlanivimab and etesevima |
Long Description | Injection, bamlanivimab and etesevimab, 2100 mg |
Pricing indicator | 54 |
Coverage code | C |
ASC payment group code | |
BETOS2 code | O1G |
Action code | N |
Type of service | V |
Effective date | 2021-02-09 |
Date Added | 2021-02-09 |
Drug Details
-
Bamlanivimab and etesevimab injection is used in certain non-hospitalized adults, children, and infants including newborns, and who have certain medical conditions that make them at higher risk for developing severe COVID-19 symptoms, including hospitalization or death:
-
to treat mild to moderate symptoms of COVID-19.
-
to prevent COVID-19 in those who are not fully vaccinated against COVID-19 or who are vaccinated, but have a weakened immune system, or are taking a medication that affects the immune system and who have had close contact or are at high risk of close contact to someone who is infected with the SARS-CoV-2 virus (for example, nursing homes, prisons).
-
-
Bamlanivimab and etesevimab is also used to treat mild to moderate symptoms of COVID-19 in hospitalized children and infants less than 2 years of age, including newborns.
-
Bamlanivimab and etesevimab are in a class called monoclonal antibodies. These medications work by blocking the action of a certain natural substance in the body to stop the spread of the virus.